raditional supercomputer vendors pushing miniaturized versions of their big machines, like Cray with its CX1, or NEC with its SX-9, have definitely been endorsed by pockets of life sciences researchers, but certainly not on any widespread scale. GPU chip maker NVIDIA even has its own personal supercomputer offering in an effort to capitalize on the growing use of graphics chips in scientific computing. And according to market research firms like IDC's High Performance Computing group, personal supercomputers that cluster together GPUs and CPUs are a definite boon to pharmaceutical research shops. And with the steadily climbing growth of workgroup systems selling for less than $100,000, what's the problem?